Science |Arcus Biosciences
Arcus Biosciences Announces Pricing of $250 Million Public Offering of Common Stock
October 21, 2026 · 10:53 PM · HAYWARD, Calif.
Arcus Biosciences, Inc. (NYSE: RCUS), a late clinical-stage biopharmaceutical company focused on developing differentiated molecules and combinations for the treatment of cancer and immune diseases, today announced the pricing of an underwritten public offering of 14,285,715 shares of its common stock at a price to the public of $17.50 per share. Gross proceeds to Arcus Biosciences from the offering are expected to be $250.0 million, before deducting underwriti...
- PublishedOctober 21, 2026 · 10:53 PM
- LocationHAYWARD, Calif.
- IndustryScience
- LanguageEN
Published by Business Wire. Read the original announcement for the full release.
Read the full announcement →